BHC
Bausch Health Companies Inc
NYSE: BHC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$5.37
+2.09% today
Updated 2026-06-05
Market cap
$1.89B
P/E ratio
—
P/S ratio
0.18x
EPS (TTM)
$-3.24
Dividend yield
—
52W range
$5 – $9
Volume
1.7M
WallStSmart proprietary scores
69
out of 100
Grade: B
Buy
Investment rating
7.3
Growth
B+5.5
Quality
C+6.5
Profitability
B6.7
Valuation
B4/9
Piotroski F-Score
Moderate
0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$7.50
+39.66%
12-Month target
$5.67
+5.59%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy0 Buy8 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 43.60% — strong efficiency
+ Free cash flow $83.00M — positive
+ Revenue growth 11.70% QoQ
+ Debt/equity -10.10x — low leverage
Risks
- Altman Z 0.26 — distress zone
- Thin margins at -11.50%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $8.12B | $8.76B | $9.63B | $10.45B | $10.53B |
| Net income | $-225.00M | $-592.00M | $-46.00M | $159.75M | $-1.40B |
| EPS | — | — | — | — | $-3.24 |
| Free cash flow | $-996.00M | $760.00M | $1.26B | $1.00B | $83.00M |
| Profit margin | -2.77% | -6.76% | -0.48% | 1.53% | -11.50% |
Peer comparison
Smart narrative
Bausch Health Companies Inc trades at $5.37. Our Smart Value Score of 69/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.26, it sits in the distress. TTM revenue stands at $10.53B. with profit margins at -11.50%.
Frequently asked questions
What is Bausch Health Companies Inc's stock price?
Bausch Health Companies Inc (BHC) trades at $5.37, on a P/S of 0.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Bausch Health Companies Inc overvalued?
Bausch Health Companies Inc carries a Smart Value Score of 69/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Bausch Health Companies Inc (BHC)?
The 12-month analyst consensus target is $7.50, about 39.7% above the current $5.37. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Bausch Health Companies Inc's revenue?
Bausch Health Companies Inc's trailing twelve-month revenue is $10.53B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Bausch Health Companies Inc's Altman Z-Score is 0.26, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.18x
ROE43.60%
Beta0.41
50D MA$5.47
200D MA$6.17
Shares out0.37B
Float0.26B
Short ratio—
Avg volume1.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—